Company Description
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E.
coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.
In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| Country | United States |
| Founded | 1982 |
| IPO Date | Apr 30, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Michael Brigham |
Contact Details
Address: 56 Evergreen Drive Portland, Maine 04103 United States | |
| Phone | 207 878 2770 |
| Website | immucell.com |
Stock Details
| Ticker Symbol | ICCC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000811641 |
| CUSIP Number | 452525306 |
| ISIN Number | US4525253062 |
| Employer ID | 01-0382980 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Michael F. Brigham | President, Chief Executive Officer, Treasurer, Secretary and Director |
| Bobbi Jo Brockmann | Vice President of Sales and Marketing and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2025 | 8-K | Current Report |
| Apr 7, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 9, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |